share_log

Johnson & Johnson | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

Johnson & Johnson | FWP: Filing under Securities Act Rules 163/433 of free writing prospectuses

强生 | FWP:自由书写募资说明书
美股sec公告 ·  05/14 17:04
Moomoo AI 已提取核心信息
Johnson & Johnson, the global healthcare company, has announced the pricing of its multi-tranche notes offering on May 14, 2024. The offering includes 3.200% notes due 2032, 3.350% notes due 2036, and 3.550% notes due 2044, with a total size of €2.5 billion. The notes are expected to settle on May 20, 2024, and will be listed on the New York Stock Exchange. The proceeds from the offering are anticipated to be used for general corporate purposes. The notes have been rated Aaa (stable) by Moody's and AAA (negative) by S&P. The joint book-running managers for the offering include J.P. Morgan Securities, Citigroup Global Markets, and several other notable financial institutions. The offering is targeted at eligible counterparties and professional clients only, with sales to EEA/UK retail investors being prohibited.
Johnson & Johnson, the global healthcare company, has announced the pricing of its multi-tranche notes offering on May 14, 2024. The offering includes 3.200% notes due 2032, 3.350% notes due 2036, and 3.550% notes due 2044, with a total size of €2.5 billion. The notes are expected to settle on May 20, 2024, and will be listed on the New York Stock Exchange. The proceeds from the offering are anticipated to be used for general corporate purposes. The notes have been rated Aaa (stable) by Moody's and AAA (negative) by S&P. The joint book-running managers for the offering include J.P. Morgan Securities, Citigroup Global Markets, and several other notable financial institutions. The offering is targeted at eligible counterparties and professional clients only, with sales to EEA/UK retail investors being prohibited.
全球医疗保健公司强生于2024年5月14日宣布了其多批票据发行的定价。此次发行包括2032年到期的3.200%的票据、2036年到期的3.350%的票据和2044年到期的3.550%的票据,总规模为25亿欧元。这些票据预计将于2024年5月20日结算,并将在纽约证券交易所上市。此次发行的收益预计将用于一般公司用途。这些票据被穆迪评为Aaa(稳定),标准普尔将这些票据评为AAA(负值)。此次发行的联合账面管理人包括摩根大通证券、花旗集团环球市场和其他几家知名金融机构。此次发行仅针对符合条件的交易对手和专业客户,禁止向欧洲经济区/英国散户投资者进行销售。
全球医疗保健公司强生于2024年5月14日宣布了其多批票据发行的定价。此次发行包括2032年到期的3.200%的票据、2036年到期的3.350%的票据和2044年到期的3.550%的票据,总规模为25亿欧元。这些票据预计将于2024年5月20日结算,并将在纽约证券交易所上市。此次发行的收益预计将用于一般公司用途。这些票据被穆迪评为Aaa(稳定),标准普尔将这些票据评为AAA(负值)。此次发行的联合账面管理人包括摩根大通证券、花旗集团环球市场和其他几家知名金融机构。此次发行仅针对符合条件的交易对手和专业客户,禁止向欧洲经济区/英国散户投资者进行销售。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息